Related Experiment Video
Updated: Aug 31, 2025
11:06
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
2.2K
Celastrol: A Promising Agent Fighting against Cardiovascular Diseases
Zhexi Li1, Jingyi Zhang2, Xulei Duan1
1Department of Cardiology, Life Science Research Center, The First Affiliated Hospital of Xinxiang Medical University, Weihui 453100, China.
Antioxidants (Basel, Switzerland)
|August 26, 2022
Summary
Celastrol, a compound from Tripterygium wilfordii, shows promise for treating cardiovascular diseases (CVD) by protecting heart cells and reducing inflammation and oxidation. Further research is needed due to pharmacokinetic limitations.
Area of Science:
- Pharmacology
- Cardiology
- Natural Products
Background:
- Cardiovascular diseases (CVD) represent a major global health burden.
- There is an urgent need for novel therapeutic strategies to combat CVD.
- Celastrol, a natural compound, has emerged as a potential therapeutic agent for CVD.
Purpose of the Study:
- To review the beneficial effects of celastrol against various cardiovascular diseases (CVD).
- To elucidate the underlying mechanisms of celastrol's cardioprotective actions.
- To discuss pharmacokinetic limitations and future directions for celastrol's clinical application.
Main Methods:
- Literature review of in vitro and in vivo preclinical studies.
- Analysis of celastrol's effects on cardiomyocyte health, oxidation, and inflammation.
- Evaluation of pharmacokinetic data and clinical potential.
Main Results:
- Celastrol demonstrates protective effects against a wide range of CVD, including obesity, diabetes, atherosclerosis, and heart failure.
- Mechanisms involve direct protection of cardiomyocytes and indirect modulation of oxidative stress and inflammation.
- Preclinical studies support celastrol's therapeutic potential for cardiovascular conditions.
Conclusions:
- Celastrol exhibits significant therapeutic potential for cardiovascular diseases (CVD) through multifaceted mechanisms.
- Pharmacokinetic challenges need to be addressed for successful clinical translation.
- Further research is warranted to optimize celastrol-based therapies for CVD management.
More Related Videos
Related Concept Videos
01:26Atherosclerosis III: Management
26
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
26
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
562
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
562
01:26Coronary Artery Disease IV: Preventive Measures
31
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
31
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
3.1K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.1K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
619
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
619
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
351
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
351